Mesa Laboratories (NASDAQ:MLAB) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Mesa Laboratories (NASDAQ:MLAB) had its target price increased by stock analysts at Wells Fargo & Company from $75.00 to $83.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has an “equal weight” rating on the medical instruments supplier’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 5.56% from the company’s current price.

Several other equities analysts have also weighed in on the company. Wall Street Zen raised Mesa Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Zacks Research raised Mesa Laboratories to a “strong sell” rating in a research note on Thursday, December 11th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Mesa Laboratories in a research report on Wednesday, October 8th. One analyst has rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Sell” and an average target price of $83.00.

Mesa Laboratories Stock Performance

Shares of Mesa Laboratories stock opened at $78.63 on Monday. The firm has a fifty day moving average of $75.83 and a two-hundred day moving average of $77.38. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.44 and a current ratio of 2.02. The stock has a market capitalization of $434.04 million, a price-to-earnings ratio of -245.72 and a beta of 0.90. Mesa Laboratories has a 52 week low of $55.45 and a 52 week high of $155.12.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Tudor Investment Corp ET AL raised its holdings in shares of Mesa Laboratories by 50.9% during the third quarter. Tudor Investment Corp ET AL now owns 6,341 shares of the medical instruments supplier’s stock worth $425,000 after acquiring an additional 2,139 shares during the period. Jacobs Levy Equity Management Inc. bought a new position in Mesa Laboratories during the 3rd quarter worth about $258,000. Qube Research & Technologies Ltd raised its stake in shares of Mesa Laboratories by 54.4% in the 3rd quarter. Qube Research & Technologies Ltd now owns 30,725 shares of the medical instruments supplier’s stock valued at $2,059,000 after purchasing an additional 10,827 shares during the period. Numerai GP LLC bought a new stake in shares of Mesa Laboratories in the third quarter valued at about $242,000. Finally, Mason Capital Management LLC bought a new stake in shares of Mesa Laboratories in the third quarter valued at about $4,711,000. Institutional investors own 90.60% of the company’s stock.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.